Last reviewed · How we verify
Tretinoin 0.05%
Tretinoin is a retinoid that binds to retinoic acid receptors to regulate gene expression, promoting cell differentiation and reducing sebum production and comedone formation.
Tretinoin is a retinoid that binds to retinoic acid receptors to regulate gene expression, promoting cell differentiation and reducing sebum production and comedone formation. Used for Acne vulgaris, Photoaged skin and wrinkles, Keratosis pilaris.
At a glance
| Generic name | Tretinoin 0.05% |
|---|---|
| Also known as | Retacnyl |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Retinoid |
| Target | Retinoic acid receptors (RAR-α, RAR-β, RAR-γ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Tretinoin activates nuclear retinoic acid receptors (RAR-α, RAR-β, RAR-γ), which modulate transcription of genes involved in cell proliferation and differentiation. In the skin, it increases cell turnover, normalizes keratinization, reduces sebaceous gland activity, and has anti-inflammatory effects. These actions make it effective for treating acne and photoaged skin.
Approved indications
- Acne vulgaris
- Photoaged skin and wrinkles
- Keratosis pilaris
Common side effects
- Erythema and irritation
- Peeling and dryness
- Photosensitivity
- Burning or stinging
Key clinical trials
- Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome (PHASE2, PHASE3)
- Treatment of Plane Warts With Topical and Oral Retinoids (PHASE4)
- Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma (NA)
- Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma. (PHASE2)
- Comparison Of Outcome Of Treatment OF Topical 15%TCA VS Topical 0.05% Tretinoin In Treatment Of Acanthosis Nigricans (NA)
- Microneedle Versus Fractional CO₂ Laser for Skin Aging Treatment With Stem Cell Secretome in Indonesian Adult Women (NA)
- Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma (PHASE4)
- Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tretinoin 0.05% CI brief — competitive landscape report
- Tretinoin 0.05% updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI